Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
29 hedge funds and large institutions have $33.7M invested in Carisma Therapeutics in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2% less capital invested
Capital invested by funds: $34.3M → $33.7M (-$639K)
3% less funds holding
Funds holding: 30 → 29 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.13M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$94.3K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$78.1K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$63.9K |
| 5 |
Bank of New York Mellon
New York
|
+$58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$223K |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$99K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$80K |
| 4 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$42K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.2K |
CARM Hedge Fund Activity: Q4 2015 in Review
29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2015, worth a combined $33.7M — down 1.9% from $34.3M a quarter earlier.
Fund positioning in CARM was balanced in Q4 2015: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 5 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.13M. The largest seller was Rotella Capital Management, cutting an estimated $223K.
- 29 institutional investors held Carisma Therapeutics (CARM) as of Q4 2015, down from 30 in Q3 2015.
- Funds reported $33.7M of Carisma Therapeutics stock for Q4 2015, down 1.9% quarter-over-quarter.
- 6 funds opened new Carisma Therapeutics positions in Q4 2015 and 6 closed out, a net change of 0 holders.
- The largest Carisma Therapeutics buyer in Q4 2015 was Franklin Resources, an estimated $1.13M added.
- The largest Carisma Therapeutics seller in Q4 2015 was Rotella Capital Management, an estimated $223K sold.
Based on aggregated 13F filings for Q4 2015.